KEYSTONE-001
Regimen
- Experimental
- neoadjuvant pembrolizumab + chemotherapy (3 cycles) + robot-assisted surgery
Population
Locally advanced resectable ESCC
Key finding
MPR 72%, pCR 41%; 2y OS 91%, 2y DFS 89%. No grade ≥3 AEs during neoadjuvant phase.
Source: PMID 39406186